Skip to main content

Intravenous magnesium sulfate does not increase ventricular CSF ionized magnesium concentration of patients with intracranial hypertension.

Publication ,  Journal Article
Brewer, RP; Parra, A; Borel, CO; Hopkins, MB; Reynolds, JD
Published in: Clin Neuropharmacol
2001

Magnesium sulfate has attracted interest as a potential neuroprotectant but passage of magnesium ion into the central nervous system has not been well documented. For this study, we quantified plasma and cerebrospinal fluid (CSF) ionized magnesium concentration after systemic magnesium sulfate infusion in patients with intracranial hypertension. Patients ( N = 9) received an intravenous infusion of 5 g/20 mmol magnesium sulfate (125 mL of a 4% wt/vol solution) over 30 minutes. Before and after dosing, CSF (from an indwelling ventricular catheter) and blood samples were collected at hourly intervals. Ionized magnesium concentration in all samples was determined using an electrolyte analyzer. Baseline plasma and CSF ionized magnesium concentrations were 0.58 +/- 0.05 and 0.82 +/- 0.06 mmol/L, respectively. Intravenous magnesium sulfate infusion significantly increased plasma ionized magnesium concentration (peak, 0.89 +/- 0.11 mmol/L), but CSF magnesium levels did not change during the 4-hour study. Systemic administration of magnesium sulfate failed to increase CSF ionized magnesium concentration in patients with intracranial hypertension despite increasing plasma magnesium levels by >50%.

Duke Scholars

Published In

Clin Neuropharmacol

DOI

ISSN

0362-5664

Publication Date

2001

Volume

24

Issue

6

Start / End Page

341 / 345

Location

United States

Related Subject Headings

  • Neuroprotective Agents
  • Neurology & Neurosurgery
  • Middle Aged
  • Male
  • Magnesium Sulfate
  • Magnesium
  • Intracranial Hypertension
  • Infusions, Intravenous
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Brewer, R. P., Parra, A., Borel, C. O., Hopkins, M. B., & Reynolds, J. D. (2001). Intravenous magnesium sulfate does not increase ventricular CSF ionized magnesium concentration of patients with intracranial hypertension. Clin Neuropharmacol, 24(6), 341–345. https://doi.org/10.1097/00002826-200111000-00005
Brewer, R. P., A. Parra, C. O. Borel, M. B. Hopkins, and J. D. Reynolds. “Intravenous magnesium sulfate does not increase ventricular CSF ionized magnesium concentration of patients with intracranial hypertension.Clin Neuropharmacol 24, no. 6 (2001): 341–45. https://doi.org/10.1097/00002826-200111000-00005.
Brewer RP, Parra A, Borel CO, Hopkins MB, Reynolds JD. Intravenous magnesium sulfate does not increase ventricular CSF ionized magnesium concentration of patients with intracranial hypertension. Clin Neuropharmacol. 2001;24(6):341–5.
Brewer, R. P., et al. “Intravenous magnesium sulfate does not increase ventricular CSF ionized magnesium concentration of patients with intracranial hypertension.Clin Neuropharmacol, vol. 24, no. 6, 2001, pp. 341–45. Pubmed, doi:10.1097/00002826-200111000-00005.
Brewer RP, Parra A, Borel CO, Hopkins MB, Reynolds JD. Intravenous magnesium sulfate does not increase ventricular CSF ionized magnesium concentration of patients with intracranial hypertension. Clin Neuropharmacol. 2001;24(6):341–345.

Published In

Clin Neuropharmacol

DOI

ISSN

0362-5664

Publication Date

2001

Volume

24

Issue

6

Start / End Page

341 / 345

Location

United States

Related Subject Headings

  • Neuroprotective Agents
  • Neurology & Neurosurgery
  • Middle Aged
  • Male
  • Magnesium Sulfate
  • Magnesium
  • Intracranial Hypertension
  • Infusions, Intravenous
  • Humans
  • Female